Qu Biologics enrolls the first patient in new Phase 2 Crohn’s Disease clinical trial
July 25, 2018 12:53 ET
|
Qu Biologics
VANCOUVER, British Columbia, July 25, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
Treatment with Qu Biologics’ Novel Immune Therapy for Ulcerative Colitis Results in High Clinical and Endoscopic Response Rates and Histological Improvement
August 02, 2017 12:29 ET
|
Qu Biologics
VANCOUVER, British Columbia, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
High Response and Remission Rates in Anti-TNFα Naïve Patients Treated with Qu Biologics’ Novel Immune Therapy for Crohn’s Disease
April 19, 2017 15:26 ET
|
Qu Biologics
VANCOUVER, British Columbia, April 19, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...